Eisai Expands into Canada
News May 11, 2010
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. has announces the establishment of Eisai Limited in Canada, the world’s ninth largest pharmaceutical market.
As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.
“Eisai’s entrance into Canada supports our strategy to strengthen our business operations and presence in North America as we prepare for future expansion in this region”
“Eisai’s entrance into Canada supports our strategy to strengthen our business operations and presence in North America as we prepare for future expansion in this region,” said Hajime Shimizu, Chairman and CEO, Eisai Inc. “Most importantly, this new subsidiary will enable Eisai to introduce many of its first-in-class products to people living in Canada who currently do not have access to these treatments, further supporting Eisai’s human health care (hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide.”
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019